Please enable JavaScript.
Coggle requires JavaScript to display documents.
Catch Up (Growth Brands (Tecentriq (Lung
2nd Line NSCLC approval in…
Catch Up
Growth Brands
Ocrevus
RRMS MA achieved December '17, NICE/SMC Reimbursement expected Oct'18 FAD, first sales in April '18.
'19 34.6m
Strategy focused on Efficacy-tolerability-convenience
Key concern if restricted RRMS access. By far largest market share.
Appraisal Consultation Document (ACD) negative for RRMS. Not uncommon, may need to modify the Patient Access Scheme to ensure broad access in RRMS. Re-submission entered into at end of April.
Tecentriq
Lung
2nd Line NSCLC approval in Apr'18. Moves to baseline funding away from CDF.
Keytruda (Prembrolizumab) Authorisation to move from CDF (access restricted to high PDL-1 expression).
Scotland SMC Mar'18 Neg response, May '18 report to be published why.
Third to Market behind Keytruda & Opdiva, free stock scheme completed by rivals first
Bladder
EAMS 1st line Sysplatin inelligible - no new patients because Authorisation & Reimbursement licenced.
On 4th NICE Committee meeting for 2nd line awaiting FAD publication. PRevious failure.
SMC - 1st line Neg guidance published. Lack of clinical benefit demonstrated vs Chemo, awaiting feedback.
New Indications
1st Line NSCLC submission starting September, FAD submission April 19
1st line RCC submission starting Q1 2019 m FAD submission Q3 19
3rd line CRC did not meet primary end pint of imblaze 370 trial & Cotellic
-
-
What have I done?
-
-
TPaTT & TPaTT Analytics
Simplify, saves time, transparency
-
Restructure
Support Data Analysis for Allocations, FTE savings & Tactical project savings - confidential
Structure for Long Term, could have looked for 20% but 10% cut supports ability to drive long term success
-
-
-
-
UK Environment
Financial Pressures - funding gap grows, forecasted fall in budget is £2.8bn - argument of spending more on medications does not wash, communicate value true value to patients
-
Current Sales Picture
92% vs YTD T0
£14m off T0 YTD
=92%
Actemra - £2.4m 88% JAK's (Janus Kinase Inhibitors) oral convenience. GCA expected to lift for year end.
Avastin - 86% high value accounts in England & Scotland patient share reduction.
Tecentriq - 86% 2nd Line lung driving growth, 3rd to market, challenge.
Mabthera £8.4m 61% - Bx erosion
OPEX
£2m under, IFT project spend Medical & Promotional
-